- Home
- ADAG vs BCAB Comparison
ADAG vs BCAB Comparison
Compare ADAG & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADAG | BCAB |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.8M | 71.6M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ADAG | BCAB |
|---|---|---|
| Price | $1.93 | $0.66 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 3 |
| Target Price | ★ $8.00 | $1.00 |
| AVG Volume (30 Days) | 73.7K | ★ 1.1M |
| Earning Date | 08-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $103,204.00 | N/A |
| Revenue This Year | $6,983.06 | N/A |
| Revenue Next Year | $36.05 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.30 | $0.24 |
| 52 Week High | $3.16 | $1.43 |
Technical Indicators
Market Signals| Indicator | ADAG | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 49.37 | 40.18 |
| Support Level | $1.76 | $0.74 |
| Resistance Level | $1.90 | $0.83 |
| Average True Range (ATR) | 0.15 | 0.08 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 53.19 | 14.83 |
Price Performance
Historical ComparisonAbout ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.